{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T03:16:28Z","timestamp":1768446988244,"version":"3.49.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Sequestration in the bone marrow niche may allow leukemic stem cells to evade exposure to drugs. Because the CXCR4\/SDF-1 axis is an important mechanism of leukemic stem cell interaction with marrow stroma, we tested whether plerixafor, an antagonist of CXCR4, may dislodge chronic myeloid leukemia (CML) cells from the niche, sensitizing them to tyrosine kinase inhibitors. We initially treated mice with retrovirally induced CML-like disease with imatinib plus plerixafor. Plerixafor mobilized CXCR4+ cells, but no difference was observed in leukemia burden, possibly reflecting insufficient disease control by imatinib. In a second series of experiments, we tested the combination of plerixafor with dasatinib in the same as well as an attenuated CML model. Despite much improved leukemia control, plerixafor failed to reduce leukemia burden over dasatinib alone. In addition, mice receiving plerixafor had an increased incidence of neurologic symptoms in association with CNS infiltration by BCR-ABL\u2013expressing cells. We conclude that plerixafor is ineffective in reducing leukemia burden in this model but promotes CNS infiltration. Beneficial effects of combining tyrosine kinase inhibitors with plerixafor may be observed in a situation of minimal residual disease, but caution is warranted when disease control is incomplete.<\/jats:p>","DOI":"10.1182\/blood-2011-05-355396","type":"journal-article","created":{"date-parts":[[2012,8,14]],"date-time":"2012-08-14T03:56:58Z","timestamp":1344916618000},"page":"2658-2668","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":35,"title":["Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML"],"prefix":"10.1182","volume":"120","author":[{"given":"Anupriya","family":"Agarwal","sequence":"first","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela G.","family":"Fleischman","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis L.","family":"Petersen","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"MacKenzie","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Luty","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Loriaux","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"},{"name":"Howard Hughes Medical Institute, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall L.","family":"Woltjer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Oregon Health & Science University, Portland, OR; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Deininger","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Knight Cancer Institute,"},{"name":"Huntsman Cancer Institute, University of Utah, Salt Lake City, UT"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2019111809361137600_B1","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia.","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"issue":"23","key":"2019111809361137600_B2","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"15","key":"2019111809361137600_B3","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.","volume":"349","author":"Hughes","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111809361137600_B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"issue":"1","key":"2019111809361137600_B5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111809361137600_B6","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2004-03-1114","article-title":"Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment.","volume":"105","author":"Chu","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2019111809361137600_B7","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity.","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"issue":"6","key":"2019111809361137600_B8","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"8","key":"2019111809361137600_B9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1038\/sj.leu.2402179","article-title":"Cell adhesion-mediated drug resistance (CAM-DR) protects the K562 chronic myelogenous leukemia cell line from apoptosis induced by BCR\/ABL inhibition, cytotoxic drugs, and gamma-irradiation.","volume":"15","author":"Damiano","year":"2001","journal-title":"Leukemia"},{"issue":"6","key":"2019111809361137600_B10","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1182\/blood-2009-01-202606","article-title":"The leukemic stem cell niche: current concepts and therapeutic opportunities.","volume":"114","author":"Lane","year":"2009","journal-title":"Blood"},{"issue":"5","key":"2019111809361137600_B11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1182\/blood.V93.5.1658","article-title":"Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.","volume":"93","author":"Damiano","year":"1999","journal-title":"Blood"},{"issue":"2","key":"2019111809361137600_B12","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1182\/blood.V78.2.499.499","article-title":"Interferon-alpha overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells.","volume":"78","author":"Dowding","year":"1991","journal-title":"Blood"},{"issue":"11","key":"2019111809361137600_B13","doi-asserted-by":"crossref","first-page":"4122","DOI":"10.1182\/blood.V99.11.4122","article-title":"BCR-ABL-induced adhesion defects are tyrosine kinase-independent.","volume":"99","author":"Wertheim","year":"2002","journal-title":"Blood"},{"issue":"22","key":"2019111809361137600_B14","doi-asserted-by":"crossref","first-page":"14320","DOI":"10.1074\/jbc.272.22.14320","article-title":"Differential signaling after beta1 integrin ligation is mediated through binding of CRKL to p120(CBL) and p110(HEF1).","volume":"272","author":"Sattler","year":"1997","journal-title":"J Biol Chem"},{"issue":"12","key":"2019111809361137600_B15","first-page":"4233","article-title":"The BCR\/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha.","volume":"94","author":"Salgia","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111809361137600_B16","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20020519","article-title":"Crosstalk between BCR\/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells.","volume":"196","author":"Ptasznik","year":"2002","journal-title":"J Exp Med"},{"issue":"7","key":"2019111809361137600_B17","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/0008-5472.CAN-04-2152","article-title":"p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.","volume":"65","author":"Geay","year":"2005","journal-title":"Cancer Res"},{"issue":"1","key":"2019111809361137600_B18","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1158\/1535-7163.MCT-07-0042","article-title":"CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.","volume":"7","author":"Jin","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2019111809361137600_B19","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-4614-1960-0_18","article-title":"CXCR4 antagonists for the treatment of CML.","volume-title":"Novel Developments in Stem Cell Mobilization: Focus on CXCR4","author":"Agarwal","year":"2012"},{"issue":"7","key":"2019111809361137600_B20","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1634\/stemcells.2004-0342","article-title":"Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis.","volume":"23","author":"Kucia","year":"2005","journal-title":"Stem Cells"},{"issue":"6","key":"2019111809361137600_B21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.2004.07.131","article-title":"Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma.","volume":"22","author":"Devine","year":"2004","journal-title":"J Clin Oncol"},{"issue":"8","key":"2019111809361137600_B22","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1182\/blood-2003-02-0663","article-title":"Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist.","volume":"102","author":"Liles","year":"2003","journal-title":"Blood"},{"issue":"23","key":"2019111809361137600_B23","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"issue":"18","key":"2019111809361137600_B24","doi-asserted-by":"crossref","first-page":"4341","DOI":"10.1182\/blood-2008-10-186668","article-title":"CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.","volume":"113","author":"Azab","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111809361137600_B25","doi-asserted-by":"crossref","first-page":"6206","DOI":"10.1182\/blood-2008-06-162123","article-title":"Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100.","volume":"113","author":"Nervi","year":"2009","journal-title":"Blood"},{"issue":"24","key":"2019111809361137600_B26","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1182\/blood-2008-05-158311","article-title":"Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.","volume":"113","author":"Zeng","year":"2009","journal-title":"Blood"},{"issue":"12","key":"2019111809361137600_B27","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1038\/leu.2008.238","article-title":"The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.","volume":"22","author":"Tavor","year":"2008","journal-title":"Leukemia"},{"issue":"5","key":"2019111809361137600_B28","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1182\/blood-2007-09-113860","article-title":"Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.","volume":"112","author":"Agarwal","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111809361137600_B29","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.","volume":"12","author":"Luo","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2019111809361137600_B30","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1128\/AAC.44.6.1667-1673.2000","article-title":"Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.","volume":"44","author":"Hendrix","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2019111809361137600_B31","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/sj.leu.2404684","article-title":"CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment.","volume":"21","author":"Juarez","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"2019111809361137600_B32","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.360","article-title":"Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.","volume":"26","author":"Weisberg","year":"2012","journal-title":"Leukemia"},{"issue":"9","key":"2019111809361137600_B33","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood.V98.9.2808","article-title":"Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.","volume":"98","author":"Wolff","year":"2001","journal-title":"Blood"},{"issue":"8","key":"2019111809361137600_B34","first-page":"1469","article-title":"Tyrosine phosphorylation of murine Crkl.","volume":"11","author":"de Jong","year":"1995","journal-title":"Oncogene"},{"key":"2019111809361137600_B35","first-page":"1432","article-title":"The CXCR4 inhibitor plerixafor effectively mobilizes primary AML in NODscid IL2R c\u2212\/\u2212 xenografts and markedly reduces but does not eradicate leukemia in combination with cytarabine +\/\u2212 clofarabine chemotherapy.","author":"Chien","year":"2011","journal-title":"Am Soc Hematol"},{"issue":"12","key":"2019111809361137600_B36","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1182\/blood-2002-10-3059","article-title":"The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr\/Abl-induced leukemia.","volume":"101","author":"Wolff","year":"2003","journal-title":"Blood"},{"issue":"4","key":"2019111809361137600_B37","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2141.2007.06590.x","article-title":"The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target.","volume":"137","author":"Burger","year":"2007","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111809361137600_B38","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1038\/leu.2011.76","article-title":"Combination of drug therapy in acute lymphoblastic leukemia with a CXCR4 antagonist.","volume":"25","author":"Parameswaran","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"2019111809361137600_B39","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/leu.2009.302","article-title":"Development of resistance to dasatinib in Bcr\/Abl-positive acute lymphoblastic leukemia.","volume":"24","author":"Fei","year":"2010","journal-title":"Leukemia"},{"issue":"4","key":"2019111809361137600_B40","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"issue":"5","key":"2019111809361137600_B41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/1535-7163.MCT-07-2331","article-title":"Stromal-mediated protection of tyrosine kinase inhibitor-treated BCR-ABL-expressing leukemia cells.","volume":"7","author":"Weisberg","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"2019111809361137600_B42","doi-asserted-by":"crossref","article-title":"Role of bone marrow derived cells in response to ionizing radiation in normal brain [abstract].","author":"Burrell","DOI":"10.1158\/1538-7445.AM2011-566"},{"key":"2019111809361137600_B43","volume-title":"Mozobil (plerixafor injection) product monograph","author":"Genzyme","year":"2009"},{"issue":"17","key":"2019111809361137600_B44","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1182\/blood-2011-10-383406","article-title":"A phase 1\/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.","volume":"119","author":"Uy","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/13\/2658\/1358188\/zh803912002658.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/120\/13\/2658\/1358188\/zh803912002658.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T15:32:41Z","timestamp":1574091161000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/120\/13\/2658\/30796\/Effects-of-plerixafor-in-combination-with-BCRABL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,27]]},"references-count":44,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2012,9,27]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-05-355396","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,27]]}}}